Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 404 across all filing types
Latest filing 2023-11-17 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a shareholder request form for receiving financial statements and MD&A documents from Revive Therapeutics Ltd. It references Canadian Securities Administrator's National Instrument 51-102 regarding continuous disclosure obligations. The text is a form for shareholders to request annual or interim financial statements and MD&A by mail or electronically. It does not contain any actual financial data, analysis, or report content. The document length is 4050 characters, which is relatively short and consistent with a request or notification rather than a full report. Therefore, this document is an announcement or request related to report distribution, not the report itself. According to the classification rules, such documents are best classified as Regulatory Filings (RNS) because they do not fit other specific categories and are not the reports themselves.
2023-11-17 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Voting Instruction Form (VIF) for the Annual & Special Meeting of shareholders of Revive Therapeutics Ltd. It includes details about the meeting date, proxy deadline, instructions on how to vote, appointment of proxy, and resolutions to be approved such as election of directors and appointment of auditors. It references the management information circular and financial statements being available electronically but does not contain the actual financial statements or detailed report content itself. The document is clearly a proxy solicitation and voting instruction material related to the upcoming Annual General Meeting (AGM). Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2023-11-17 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled as a "Notice of Meeting" and "Management Information Circular" for the Annual and Special Meeting of Shareholders of Revive Therapeutics Ltd. It includes details about the meeting agenda such as receiving audited consolidated financial statements, electing directors, appointing auditors, and approving stock option plans. It also provides proxy voting instructions and information about the meeting logistics. The document is clearly a solicitation of proxies and information for shareholders to vote at the upcoming annual general meeting. It is not the annual report itself, nor is it the voting results or a financial report. The presence of the term "Management Information Circular" and the detailed proxy solicitation confirms this is a Proxy Solicitation & Information Statement. The document length (15,000 characters) and content confirm it is the full circular, not just an announcement or a brief notice. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2023-11-17 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders for Revive Therapeutics Ltd. It details the date, location, agenda items including receiving audited financial statements, electing directors, appointing auditors, and other shareholder meeting business. It also provides instructions on proxy voting and access to meeting materials. The document is a formal notice for the upcoming shareholder meeting rather than the meeting materials themselves or the results of the meeting. It does not contain financial statements or detailed reports but serves as an announcement to shareholders about the meeting and how to participate. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices of such meetings.
2023-11-17 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for the Annual & Special Meeting of shareholders of Revive Therapeutics Ltd. It includes instructions for voting, appointment of proxyholders, and details about the meeting date and proxy deadline. It also references the availability of meeting materials electronically and the use of notice-and-access for proxy solicitation. The content is focused on soliciting votes and providing proxy voting instructions rather than presenting financial data or management discussion. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI).
2023-11-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive licensing agreement between Revive Therapeutics and Lawson Health Research Institute to develop and commercialize a novel diagnostic test for long COVID. It contains no financial statements, regulatory filings, or detailed financial performance data. It is a corporate announcement about a business development and research collaboration, not a financial report, earnings release, or regulatory filing. The document length is 8548 characters, which is substantial but the content is clearly a news announcement about a licensing agreement and product development. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2023-11-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.